AAD releases new guidelines for the tx of cutaneous melanoma

(HealthDay)—New guidelines have been released for the treatment of primary cutaneous melanoma, according to a report from the American Academy of Dermatology published online Nov. 1 in theJourna

Updated on: March 27,2024

AAD releases new guidelines for the tx of cutaneous melanoma

(HealthDay)—New guidelines have been released for the treatment of primary cutaneous melanoma, according to a report from the American Academy of Dermatology published online Nov. 1 in theJourna

Updated on:March 27,2024

Swallowable device to detect Barrett's esophagus receives FDA 510(k) clearance

by Case Western Reserve University"FDA clearance of the EsoCheck device means the device is now available to patients and physicians as a non-endoscopic method for sampling the esophagus. Th

Updated on: May 09,2024

Swallowable device to detect Barrett's esophagus receives FDA 510(k) clearance

by Case Western Reserve University"FDA clearance of the EsoCheck device means the device is now available to patients and physicians as a non-endoscopic method for sampling the esophagus. Th

Updated on:May 09,2024

Researchers develop CAR T cells that fight prostate cancer in bone

by H. Lee Moffitt Cancer Center & Research InstituteBTN expression and spontaneous gamma/delta T cell infiltration in prostate tumors. (A) Bioinformatic analysis of TCR gamma variable regions

Updated on: February 20,2024

Researchers develop CAR T cells that fight prostate cancer in bone

by H. Lee Moffitt Cancer Center & Research InstituteBTN expression and spontaneous gamma/delta T cell infiltration in prostate tumors. (A) Bioinformatic analysis of TCR gamma variable regions

Updated on:February 20,2024

Cancer drug that targets two immune-evading tumor tactics performs well in early clinical trial

by University of PittsburghCredit: CC0 Public DomainA "two-for-one" cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scient

Updated on: April 14,2024

Cancer drug that targets two immune-evading tumor tactics performs well in early clinical trial

by University of PittsburghCredit: CC0 Public DomainA "two-for-one" cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scient

Updated on:April 14,2024

Findings challenge standard understanding of COVID-19 infection

by Iqbal Pittalwala,University of California - RiversideCredit: Pixabay/CC0 Public DomainSome viruses move between species. For example, SARS-CoV-2, the virus that causes COVID-19, can spill ove

Updated on: June 28,2024

Findings challenge standard understanding of COVID-19 infection

by Iqbal Pittalwala,University of California - RiversideCredit: Pixabay/CC0 Public DomainSome viruses move between species. For example, SARS-CoV-2, the virus that causes COVID-19, can spill ove

Updated on:June 28,2024

New strategy for treating the most aggressive type of brain cancer

by Maria Fernanda Ziegler,FAPESPCredit: CC0 Public DomainResearchers from the University of São Paulo (USP) in Brazil have developed a strategy for treating the most aggressive type of brain can

Updated on: April 09,2024

New strategy for treating the most aggressive type of brain cancer

by Maria Fernanda Ziegler,FAPESPCredit: CC0 Public DomainResearchers from the University of São Paulo (USP) in Brazil have developed a strategy for treating the most aggressive type of brain can

Updated on:April 09,2024

Woman sues L'Oreal over claim hair straightener spurred uterine cancer

by Cara MurezA Missouri woman has sued L'Oréal and several other beauty product companies, alleging that their hair-straightening products caused heruterine cancer.Thelawsuitclai

Updated on: February 18,2024

Woman sues L'Oreal over claim hair straightener spurred uterine cancer

by Cara MurezA Missouri woman has sued L'Oréal and several other beauty product companies, alleging that their hair-straightening products caused heruterine cancer.Thelawsuitclai

Updated on:February 18,2024

Cancers in adults under 50 are on the rise globally

byBrigham and Women's HospitalCredit: Unsplash/CC0 Public DomainOver recent decades, more and more adults under the age of 50 are developing cancer. A study conducted by researchers from Bri

Updated on: January 02,2024

Cancers in adults under 50 are on the rise globally

byBrigham and Women's HospitalCredit: Unsplash/CC0 Public DomainOver recent decades, more and more adults under the age of 50 are developing cancer. A study conducted by researchers from Bri

Updated on:January 02,2024

A barrier that keeps cancer at bay

by Ecole Polytechnique Federale de LausanneLoss of a barrier to tumor formation: On the left, a protective barrier of activin B expression (red color) is present in normal pancreatic islets. On t

Updated on: March 27,2024

A barrier that keeps cancer at bay

by Ecole Polytechnique Federale de LausanneLoss of a barrier to tumor formation: On the left, a protective barrier of activin B expression (red color) is present in normal pancreatic islets. On t

Updated on:March 27,2024

How tumors mutate their way out of a crisis—and become drug resistant in the process

byWeizmann Institute of ScienceHuman lung cancer cells under the microscope, before (left) and after (right) treatment with an anticancer drug, which causes DNA breaks (green) in the cell nuclei

Updated on: January 21,2024

How tumors mutate their way out of a crisis—and become drug resistant in the process

byWeizmann Institute of ScienceHuman lung cancer cells under the microscope, before (left) and after (right) treatment with an anticancer drug, which causes DNA breaks (green) in the cell nuclei

Updated on:January 21,2024

Novel FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer

by Vall d'Hebron Institute of OncologyIntermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithel

Updated on: January 11,2024

Novel FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer

by Vall d'Hebron Institute of OncologyIntermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithel

Updated on:January 11,2024

Study reveals aggressive prostate cancer linked to ancestral heritage

byUniversity of SydneyCredit:Nature(2022). DOI: 10.1038/s41586-022-05154-6Two pioneering studies published simultaneously today inNatureandGenome Medicine, have ide

Updated on: January 22,2024

Study reveals aggressive prostate cancer linked to ancestral heritage

byUniversity of SydneyCredit:Nature(2022). DOI: 10.1038/s41586-022-05154-6Two pioneering studies published simultaneously today inNatureandGenome Medicine, have ide

Updated on:January 22,2024